2001
DOI: 10.1159/000045922
|View full text |Cite
|
Sign up to set email alerts
|

Polymorphism in Methylenetetrahydrofolate Reductase Gene: Its Impact on Plasma Homocysteine Levels and Carotid Atherosclerosis in ESRD Patients Receiving Hemodialysis

Abstract: The methylenetetrahydrofolate reductase (MTHFR) gene polymorphism has been shown to be associated with cardiovascular disease in healthy subjects as well as in patients with end-stage renal disease (ESRD). In this study, we examined the allelic frequency and genotype distribution of the MTHFR gene in 151 Chinese ESRD patients receiving hemodialysis and 135 healthy controls. In addition, we investigated the relationship between the MTHFR gene polymorphism and the plasma homocysteine (Hcy) level as well as the i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
23
0

Year Published

2002
2002
2009
2009

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 36 publications
(26 citation statements)
references
References 31 publications
3
23
0
Order By: Relevance
“…The TDT analysis revealed no significant deviation in the transmission of the MTHFR C677T alleles both in dialyzed and conservatively treated CRF patients, thus suggesting no impact of this polymorphism on the risk of the development of end-stage renal disease. Similar results were obtained in the case-control study of Lim et al [16], where 151 Taiwanese patients on maintenance hemodialysis presented MTHFR genotype distribution similar to 135 healthy subjects. As previously shown in the study of Kimura et al [11], our subpopulation of dialyzed CRF patients carrying TT genotype tended to be younger at time of the study and at initiation of renal replacement therapy (p = 0.06, table 3), also with shorter time from diagnosis of chronic renal failure to the onset of renal replacement therapy (5.5 ± 7.2, 7.0 ± 5.4, 8.2 ± 6.6 years for the TT, CT and CC genotypes, respectively).…”
Section: Discussionsupporting
confidence: 87%
“…The TDT analysis revealed no significant deviation in the transmission of the MTHFR C677T alleles both in dialyzed and conservatively treated CRF patients, thus suggesting no impact of this polymorphism on the risk of the development of end-stage renal disease. Similar results were obtained in the case-control study of Lim et al [16], where 151 Taiwanese patients on maintenance hemodialysis presented MTHFR genotype distribution similar to 135 healthy subjects. As previously shown in the study of Kimura et al [11], our subpopulation of dialyzed CRF patients carrying TT genotype tended to be younger at time of the study and at initiation of renal replacement therapy (p = 0.06, table 3), also with shorter time from diagnosis of chronic renal failure to the onset of renal replacement therapy (5.5 ± 7.2, 7.0 ± 5.4, 8.2 ± 6.6 years for the TT, CT and CC genotypes, respectively).…”
Section: Discussionsupporting
confidence: 87%
“…Fukasawa et al [22] reported that the MTHFR C677T point mutation could serve as an important indicator for identifying susceptibility to arteriovenous fistulae obstruction in hemodialysis patients. The C677T mutation of the MTHFR gene was found to be an independent risk factor for carotid atherosclerosis in ESRD in one study [23].…”
Section: Discussionmentioning
confidence: 96%
“…Hyperhomocysteinemia and diabetes mellitus are both associated with premature vascular disease [9][10][11]. There are several studies concerning the molecular bases of vascular complications related to increased homocysteine levels [11][12][13]. The relationship between homocysteine levels and diabetic complications is still an unresolved issue.…”
Section: Discussionmentioning
confidence: 99%